 |
| YouTube courtesy Dana Farber |
CANCER DIGEST – June 1, 2014 – Men newly diagnosed with advanced prostate cancer that has spread to other parts of the body survived a year longer when treated with chemotherapy before undergoing hormone therapy, compared to men who received the chemotherapy after their cancer became resistant to hormone therapy. The Dana-Farber Cancer Institute clinical trial is the first to prolong survival in men newly diagnosed with metastatic prostate cancer according to lead investigator Dr. Christopher Sweeney. In the study, 790 men were randomly assigned to receive standard hormone blockade therapy or chemotherapy (Taxotere®) and hormone blockade therapy. After 29 months the median overall survival in the hormone therapy only group was 44 months compared to 57.6 months for the men who received early chemotherapy plus hormone therapy. The study was presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
No comments:
Post a Comment